期刊
EUROPEAN JOURNAL OF CANCER
卷 48, 期 18, 页码 3439-3447出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2012.07.002
关键词
Brain metastases; Clinical trail; Prophylaxis; EORTC
类别
资金
- Roche
- Novocure
- Merck Serono
- Comprehensive Cancer Center Vienna
- Genentech
- EU
- Dutch Epilepsy Foundation (NEF)
- Dutch Cancer Society (KWF Kankerbestrijding)
- Foundation NutsOhra
- Foundation STOPhersentumoren. nl
- National Brain Tumor Foundation/Tug McGraw Foundation
- UCB
- Sanofi-Aventis
- GSK
Brain metastases (BM) occur in a significant proportion of cancer patients and are associated with considerable morbidity and poor prognosis. The trial design in BM patients is particularly challenging, as many disease and patient variables, statistical issues, and the selection of appropriate end-points have to be taken into account. During a meeting organised on behalf of the European Organisation for Research and Treatment of Cancer (EORTC), methodological aspects of trial design in BM were discussed. This paper summarises the issues and potential trial strategies discussed during this meeting and may provide some guidance for the design of trials in BM patients. (C) 2012 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据